Deck 30: Asthma and Chronic Obstructive Pulmonary Disease

Question 1

Medications used in the management of patients with COPD include:

A) Inhaled beta-2-agonists
B) Inhaled anticholinergics (ipratropium)
C) Inhaled corticosteroids
D) All of the above

Answer 1

All of the above

Question 2

A stepwise approach to the pharmacologic management of asthma:

A) Begins with determining the severity of asthma and assessing asthma control
B) Is used when asthma is severe and requires daily steroids
C) Allows for each provider to determine their personal approach to the care of asthmatic patients
D) Provides a framework for the management of severe asthmatics,but is not as helpful when patients have intermittent asthma

Answer 2

Begins with determining the severity of asthma and assessing asthma control

Question 3

Education of patients with COPD who use inhaled corticosteroids includes:

A) Doubling dose at the first sign of a URI
B) Use their inhaled corticosteroid first and then their bronchodilator
C) Rinsing mouth after use
D) They should not smoke for at least 30 minutes after using

Answer 3

Rinsing mouth after use

Question 4

The first-line therapy for mild-persistent asthma is:

A) High-dose montelukast
B) Theophylline
C) Low-dose inhaled corticosteroids
D) Long-acting beta-2-agonists

Question 5

Prior to developing a plan for the treatment of asthma,the patient's asthma should be classified according to the NHLBI Expert Panel 3 guidelines.In adults mild-persistent asthma is classified as asthma symptoms that occur:

A) Daily
B) Daily and limit physical activity
C) Less than twice a week
D) More than twice a week and less than once a day

Question 6

One goal of asthma management in children is:

A) They independently manage their asthma
B) Participation in school and sports activities
C) No exacerbations
D) Minimal use of inhaled corticosteroids

Question 7

Asthma exacerbations at home are managed by the patient by:

A) Increasing frequency of beta-2-agonists and contacting their provider
B) Doubling inhaled corticosteroid dose
C) Increasing frequency of beta-2-agonists
D) Starting montelukast (Singulair)

Question 8

Treatment for mild intermittent asthma is:

A) Daily inhaled medium dose corticosteroids
B) Short-acting beta-2-agonists (albuterol)as needed
C) Long-acting beta-2-agonists every morning as a preventative
D) Montelukast (Singulair)daily

Question 9

One goal of asthma therapy outlined by the NHLBI Expert Panel 3 guidelines is:

A) Ability to use albuterol daily to control symptoms
B) Minimize exacerbations to once a month
C) Keep nighttime symptoms at a maximum of twice a week
D) Require infrequent use of beta 2 agonists (albuterol)for relief of symptoms

Question 10

Monitoring a patient with persistent asthma includes:

A) Monitoring how frequently the patient has a URI during treatment
B) Monthly in-office spirometry testing
C) Determining if the patient has increased use of his or her long-acting beta-2-agonist due to exacerbations
D) Evaluating the patient every 1 to 6 months to determine if the patient needs to step up or down in their therapy

Question 11

Pregnant patients with asthma may safely use throughout their pregnancy.

A) Oral terbutaline
B) Prednisone
C) Inhaled corticosteroids (budesonide)
D) Montelukast (Singulair)

Question 12

Patients with COPD require monitoring of:

A) Beta-2-agonist use
B) Serum electrolytes
C) Blood pressure
D) All of the above

Question 13

Patients with a COPD exacerbation may require:

A) Doubling of inhaled corticosteroid dose
B) Systemic corticosteroid burst
C) Continuous inhaled beta-2-agonists
D) Leukotriene therapy

Question 14

In children age 5 to 11 years mild-persistent asthma is diagnosed when asthma symptoms occur:

A) At nighttime one to two times a month
B) At nighttime three to four times a month
C) Less than twice a week
D) Daily

Question 15

Patients who are at risk of a fatal asthma attack include patients:

A) With moderate persistent asthma
B) With a history of requiring intubation or ICU admission for asthma
C) Who are on daily inhaled corticosteroid therapy
D) Who are pregnant